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Rates of mother-to-child transmission of HIV are falling globally with an estimated 200,000 
child infections averted in 2018 thanks to implementation of prevention of mother-to-child-
transmission (PMTCT) interventions[1]. As a result, fewer children are living with HIV and a 
growing number of children born to mothers living with HIV remain uninfected. However, 
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children who are HIV-exposed but uninfected (HEU) continue to have higher all-cause 
mortality than HIV-unexposed infants[2], primarily due to greater risk and severity of 
common childhood infections[3]. As an expanding, clinically distinct group of children, a 
greater understanding of why HEU fail to survive and thrive to the extent of HIV-unexposed 
children is warranted[3-5]. Optimal interventions, particularly those to reduce infectious 
morbidity and mortality, may well deviate from those developed for children living with HIV or 
for those who are HIV-unexposed[5]. 
 
Antimicrobial prophylaxis guidelines for HIV-exposed infants were developed prior to the 
wide availability of antiretroviral therapy (ART), when mother-to-child transmission rates, and 
subsequent infant infectious mortality, were high [6, 7]. In this context, treating HEU in the 
same way as HIV-positive infants was justified because ongoing exposure to HIV via 
breastfeeding and the challenges of infant HIV testing posed a risk that initially uninfected 
infants who subsequently acquired HIV would miss out on life-saving treatment[13]. The 
World Health Organization (WHO) recommends that all HIV-exposed infants receive 
prophylactic cotrimoxazole (CTX) from 4-6 weeks’ of age[7]; CTX is continued long-term for 
HIV-positive children living in regions with high prevalence of severe bacterial infections and 
malaria, and only discontinued for HEU upon cessation of breastfeeding and conclusive 
determination of their HIV-negative status[7]. CTX is a broad-spectrum antibiotic made up of 
two folate synthesis inhibitors (trimethoprim and sulfamethoxazole) with activity against 
Pneumocystis jirovecii and a range of other bacterial, fungal and Plasmodium species[8]. 
There is strong evidence that CTX significantly reduces infectious morbidity and mortality[8], 
and our group[9] and others[10] have recently shown that long-term continuation of CTX 
reduces systemic and intestinal levels of inflammatory mediators associated with poor 
clinical outcomes for children and adults living with HIV. The impact of CTX on the health of 
HEU is far less well supported. Although morbidity and mortality reductions have been 
observed among HEU infants living in malaria-endemic regions[11], two recent randomised 
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controlled trials in non-malarial regions show that CTX did not improve 18-month 
survival[12], 12-month survival[13] or incidence of severe pneumonia or diarrhoea[13] 
among HEU. 
 
Without strong evidence for a clinical benefit, recommendations to provide CTX prophylaxis 
to all HEU have been called into question[14, 15], particularly in light of substantial 
improvements in PMTCT coverage and early infant diagnosis of HIV since treatment 
guidelines were developed. There are rising concerns that CTX may select for antimicrobial 
resistance (AMR)[12, 16-18], which is already very high among CTX-targeted pathogens in 
many LMIC[8]. Furthermore, there is a growing understanding of how resident microbial 
populations (the microbiome) contribute to child development and long-term health[19], 
which may be disrupted by early exposure to antibiotics. Exposure to maternal HIV is 
associated with a distinct gut microbiome amongst HEU relative to HIV-unexposed 
infants[20, 21], but little is known about how this contributes to their clinical phenotype. 
Contrary to expectations that CTX might reduce diversity of the gut microbiome through its 
broad antimicrobial activity, recent studies have not identified global difference in the gut 
microbiome after long-term CTX treatment of HIV-positive ART-treated children[9] or after 
short-term treatment of a mixed population of HIV-positive and HIV-negative children[22]. At 
a species level, our group has shown that CTX specifically suppressed gut-resident 
Streptococci associated with intestinal inflammation among HIV-positive children who 
continued treatment for 84 weeks, but this was not evident for global taxa[9]. The impact of 
CTX on HEU microbiomes has not been previously assessed. 
   
In this issue of Clinical Infectious Diseases, D'Souza and colleagues provide the first 
evaluation of how CTX affects the gut microbiomes and AMR gene carriage of HEU during 
their first year of life. The sub-study is nested within a recently completed randomised 
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controlled trial among HEU in South Africa, which showed that no CTX (N=609) was not 
inferior to CTX prophylaxis administered according to WHO guidelines (N=611) for the 
prevention of severe childhood illnesses or death in an urban setting without endemic 
malaria transmission, low incidence of pneumonia and diarrhoea, and good coverage of 
PMTCT and infant HIV testing[13]. Using stool samples from a small subset of trial 
participants, this sub-study identifies a convincing signature of AMR selection over time 
amongst children who received CTX (N=34) relative to untreated controls (N=29), informing 
on a pertinent concern around the use of prophylactic antibiotics in LMIC. Despite global 
stability in the variety of genes associated with microbial taxa and their functions within 
individuals (α-diversity) in both CTX-treated and untreated groups of HEU, the abundance 
and α-diversity of trimethoprim- and sulphonamide-resistance genes increased with time 
only in the CTX-treated group. In parallel, variation between individuals in genes associated 
with microbial taxa, function and AMR (β-diversity) decreased amongst children receiving 
CTX, suggesting that prophylaxis exerted an ongoing selection pressure on the microbiome 
with continued use. These more detailed assessments are consistent with observations from 
the trial of CTX among HEU in Botswana, which reported a higher proportion of CTX-
resistant Escherichia coli isolates cultured from stool in CTX-treated versus untreated HEU 
post-randomisation[12]. 
 
A strength of the study is its randomised design and longitudinal follow-up (stool was 
sampled at 6 weeks, 4 months and 6 months), which allowed for a causal role of CTX to be 
disaggregated from potential confounding factors known to shape microbiome diversity. Few 
studies have been able to assess the early effects of CTX on the microbiome of HEU or 
infants living with HIV since CTX is standard of care for both groups[7] and microbial 
diversity changes with age, particularly in young infants in whom colonisation is ongoing[19]. 
An additional advantage of this study over previous investigations of the gut microbiome of 
HEU[20, 21], is the use of shotgun metagenomics rather than targeted 16S sequencing or 
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culture-based antimicrobial resistance testing. This metagenomics approach sequences all 
microbial genomes present in a sample rather than a subset of pre-selected species or 
marker genes[23], allowing for a less biased and more accurate assessment of microbial 
taxa, function and AMR gene carriage[23]. Whilst sequencing read-depth in this study did 
not allow for confident resolution of potential CTX-driven changes at a species- or strain-
level, the lack of global differences in α-diversity identified at a taxa-level goes some way to 
allay concerns that CTX drives dysbiosis among HEU. 
 
This sub-study excluded infants who did not provide stool samples at all three timepoints 
and 15% of infants were lost to follow-up in the wider trial[13], meaning that it likely focuses 
on children with more favourable clinical outcomes. The study is also insufficiently powered 
to draw conclusions on the clinical importance of AMR selection by CTX. Thus, selection for 
AMR genes is insufficient evidence in isolation to change current guidelines on CTX use. 
Indeed, CTX is already known to select for AMR in HIV-positive cohorts[8] and, due to its 
broad-spectrum activity, appears to do so more rapidly than more restricted-spectrum 
antibiotics[24]. However, the beneficial effects of CTX prophylaxis on morbidity, mortality and 
inflammation persist with long-term use among children and adults living with HIV despite 
high resistance rates[6, 9, 25, 26]. Concerns around AMR become more critical in the 
context of the wider trial in which this sub-study was nested, which found similar clinical 
outcomes amongst those randomised to take versus not take CTX prophylaxis[13]. 
Therefore, the risk of driving AMR carriage is not being off-set by a clinical benefit for HEU in 
this context. However, calls to change treatment guidelines for HEU on the basis of the 
evidence that CTX selects for AMR are dependent on two further as yet untested 
assumptions: (1) AMR genes will persist long-term after discontinuation of CTX; and, (2) 
AMR gene carriage will compromise clinical management of subsequent infections. Both 
concerns require validation in future studies to provide proof of harm. Another important 
consideration is that maternal CTX use may have shaped infant microbiomes prior to 
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randomisation via vertical transmission of AMR genes and/or direct exposure of infants to 
CTX in breastmilk. D’Souza and colleagues do not report on maternal CTX treatment and it 
remains plausible that the most profound effects of CTX on the infant microbiome and 
resistome occur in response to initial CTX exposure from their mothers; were this to be the 
case, changing treatment guidelines for HEU infants would not avert AMR risk.  
 
Current guidelines recommending CTX prophylaxis for HIV-exposed infants are almost 
exclusively due to the clinical benefits for HIV-positive children with limited evidence for a 
benefit for children who remain uninfected in settings where malaria is non-endemic[7]. 
Minimised vertical transmission and early and ongoing infant HIV testing reflects an ideal 
scenario for the clinical care of HIV-exposed infants, but cannot be considered the norm in 
many LMIC[7]. Therefore, a context-sensitive review of the relative risks and benefits of 
existing treatment guidelines for HEU is timely. D’Souza and colleagues provide the first 
direct evidence for AMR selection by CTX treatment of HEU in infancy using unbiased 
metagenomics, adding empirical evidence for why global antibiotic prophylaxis should be 
avoided where more targeted interventions are possible. Population-level AMR is a 
particularly critical consideration in the six countries where >10% of all children are HEU 
(eSwatini [32.4%], Botswana [27.4%], South Africa [21.6%], Lesotho [21.1%], Namibia 
[16.4%] and Zimbabwe [13.6%])[27]. Earlier and ongoing testing for HIV during infancy are 
already recommended[7]; wider implementation of such guidelines would enable CTX 
prophylaxis to be provided in a more targeted way, maintaining the essential protection 
against infections necessary for children living with HIV whilst avoiding unnecessarily 
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